Exploring the history and potential of CAR-T cell therapies

Can't see this email? View it online

	Oncology
	The latest oncology news from News Medical

Exploring the history and potential of CAR-T cell therapies

In the last ten years, chimeric antigen receptor T cells (CAR-T cells) have become the dominant driver for growth in the field of cell and gene therapy (CGT) development. The history and potential future of CAR-T cells are reviewed in this article from BioIVT.

Read the article

			Expanding research and clinical options for children with cancer In this interview, Dr. Church, the Molecular and Pediatric Pathologist at Boston Children's Hospital, talks to NewsMedical about their work in pediatric oncology, and the need to expand research and clinical options for children with cancer.

			NCCN 2024 Annual Conference focuses on practical applications for improving cancer care The National Comprehensive Cancer Network (NCCN)-;an alliance of leading cancer centers-;hosted more than 1,700 oncology professionals during the NCCN 2024 Annual Conference on April 5-7.

			Innovative cancer treatment approach yields promising results in pediatric patients Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples.

	Revolutionary therapeutic shows promise for pancreatic cancer treatment A new type of investigational therapeutic in development for pancreatic cancer has shown unprecedented tumor-fighting abilities in preclinical models of the disease, suggesting it has the potential to offer novel treatment options for nearly all pancreatic tumors, a comprehensive study has found.

	Deciphering cancer plasticity:Insights from MSK research About 90% of deaths from cancer are a result of metastasis -; that is, from cancer's ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain.

	ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with heart damage, at one month after their last chemotherapy dose compared with those who did not take an ACE inhibitor, according to a study presented at the American College of Cardiology's Annual Scientific Session.

	AI improves breast cancer screening accuracy, reduces false alarms Using artificial intelligence (AI) to supplement radiologists' evaluations of mammograms may improve breast-cancer screening by reducing false positives without missing cases of cancer, according to a study by researchers at Washington University School of Medicine in St. Louis and Whiterabbit.ai, a Silicon Valley-based technology startup.

	Understanding Prostate Cancer Disparities Through Proteogenomics Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.

Website: www.news-medical.net

Email: [email protected]

Telephone: +44 (0)161 457 7150

AZoNetwork UK Ltd.
NEO, 4th Floor
9 Charlotte Street, Manchester
M1 4ET, UK

Why did you receive this email?
You recently requested related information from us and asked to be notified of additional information.

Not interested anymore?
Unsubscribe or
Update Your Newsletter Subscriptions